PT - JOURNAL ARTICLE AU - Su, Ting-Shi AU - Zhou, Ying AU - Huang, Yong AU - Cheng, Tao AU - Liang, Ping AU - Liang, Shi-Xiong AU - Li, Le-Qun TI - Optimal Stereotactic Body Radiotherapy Dosage For Hepatocellular Carcinoma AID - 10.1101/2020.02.27.20028621 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.27.20028621 4099 - http://medrxiv.org/content/early/2020/02/27/2020.02.27.20028621.short 4100 - http://medrxiv.org/content/early/2020/02/27/2020.02.27.20028621.full AB - Background and purpose The optimal dose and fractionation scheme of stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to different tolerated liver volumes and degrees of cirrhosis. We compared the effectiveness of stereotactic body radiation therapy dosing regimens for hepatocellular carcinoma (HCC).Methods and materials This single-center retrospective study included 604 patients treated during 2011-2017. Biologically effective dose (BED10) and equivalent dose in 2 Gym fractions (EQD2) were assumed at an α/β ratio of 10. Overall survival (OS), local recurrence-free rate (LRF), intrahepatic recurrence-free rate (IRF), and progression-free survival (PFS) was evaluated in univariable and propensity-score matched analyses.Results Median tumor size was 5.2 cm (interquartile range [IQR], 1.1-21.0). Median follow-up was 31 months in surviving patients (IQR, 3-82). High radiotherapy dose correlated with better OS, PFS, LRF and IRF. Different post-SBRT OS, PFS, LRF and IRF rates were observed for stereotactic ablative radiotherapy (SART) with BED10 ≥100 Gy, SBRT with EQD2 ≥74 Gy to BED10 <100 Gy, and stereotactic conservative radiotherapy (SCRT) with EQD2 <74 Gy.Conclusions High radiotherapy dose correlated with better outcomes. If tolerated by normal tissue, we recommend SART as a first-line ablative dose or SBRT as a second-line radical dose. Otherwise, SCRT is recommended as palliative irradiation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Natural Science Foundation of China [81903257], the National Science and Technology Major Special Project [2012ZX10002010001009] and the Scientific Research and Technology Development Program of Guangxi (CN), GuiKeGong [14124003-4], and Guangxi BaGui Scholars’ Special Fund.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNone